Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace
MWN-AI** Summary
Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving solutions, has announced a significant advancement in breast cancer diagnostics. On October 16, 2025, the company revealed a sub-licensing agreement granting it exclusive global rights to the BreastCheck® test—a non-invasive, at-home screening tool designed to detect breast abnormalities. Developed through its subsidiary Odyssey Medical Devices, Inc., the test delivers results in just 15 minutes, providing an effective preliminary screening option to complement traditional mammography.
The BreastCheck® technology is officially registered with the FDA, as well as with relevant authorities in the European Union and the United Kingdom. Odyssey's CEO, Michael Redmond, emphasized the importance of early detection in enhancing breast cancer survival rates. The company estimates that in 2025, 317,000 new cases of invasive breast cancer will be diagnosed in the United States alone, highlighting the urgent need for efficient screening methods.
The breast cancer diagnostics market, currently valued at approximately $26 billion, is projected to double in the next 8-10 years, driven by advancements in technology such as AI and genomics, increasing rates of breast cancer diagnoses, and a growing emphasis on early detection. Odyssey aims to commence commercialization and generate revenue from BreastCheck® shortly, marking its transition to a revenue-generating medical technology firm.
Breast cancer, the most common cancer among women globally, accounted for around 30% of new cancer cases in U.S. women in 2025. Given the alarming trend of rising diagnoses, the BreastCheck® offers a timely solution for routine monitoring and early detection. For more details, visit the company’s website.
MWN-AI** Analysis
**Market Analysis and Investment Advice for Odyssey Health, Inc. (OTCQB: ODYY)**
Odyssey Health, Inc. has taken a significant step into the burgeoning breast cancer diagnostics market with the introduction of the BreastCheck® non-invasive test. Valued at roughly $26 billion and projected to double in the next decade, this market presents a compelling opportunity for Odyssey amidst rising global breast cancer incidence rates.
The BreastCheck® device offers a unique selling proposition: a quick, at-home test that provides immediate results. While not a substitute for mammograms, its role as a first-line screening tool aligns well with the industry's increasing focus on early detection. Given that approximately 317,000 new invasive breast cancer cases are expected in the U.S. this year, the demand for effective, accessible diagnostic tools is rising sharply.
From an investment perspective, Odyssey Health, Inc. is transitioning from a development stage to a revenue-generating entity. This shift is critical as it indicates a move towards profitability, appealing to both new and existing investors. The company's strategy of acquiring and developing innovative medical technologies positions it well for long-term growth. However, investors should remain cautious, monitoring the execution of the sub-licensing agreement, which hinges on certain closing conditions.
Key considerations for potential investors include market competition, regulatory pathways, and the pace of consumer adoption. With the device being FDA and EU registered, regulatory hurdles appear manageable, which could facilitate a swift market entry.
Investing in Odyssey Health at this juncture may provide an opportunity to capitalize on the growth potential within a critical health sector. However, as always, investors should conduct their due diligence, being aware of the inherent risks associated with emerging medical technology investments, including market acceptance and operational execution challenges. Overall, Odyssey could represent a compelling investment within the healthcare sector’s diagnostics niche.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck ® , a non-invasive test for breast abnormalities. The definitive agreement, managed through its subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The BreastCheck ® test can be done at home and takes just 15 minutes. The results are immediate and BreastCheck ® has been proven to be a reliable guide in the first stage identification of potential breast abnormalities. While BreastCheck ® is not a replacement for a mammogram, it is an effective first line screening device. The technology behind BreastCheck ® is FDA registered in the United States, and it is also registered with the relevant regulatory authorities in the European Union and the United Kingdom.
“This is a major step forward in our medical device portfolio. Early detection has significantly increased breast cancer survival rates in recent years. It is estimated that this year 317,000 new cases of invasive breast cancer will be diagnosed in women in the United States. Statistics show that 1 in 8 women in the United States will develop breast cancer in their lifetime,” said Michael Redmond, CEO of Odyssey. “The breast cancer diagnostics market is a rapidly growing sector, currently valued in the low tens of billions of dollars depending on what is included, with forecasts to double, or more, over the next 8-10 years. Growth is being driven by technological advances, such as imaging, AI, genomics, the rising incidence of breast cancer globally, greater emphasis on early detection, and expanding healthcare access especially in emerging markets.”
“We expect to begin commercialization and generate initial revenue from BreastCheck ® in the near future, marking our transition from a development-stage to a revenue-generating medtech company,” commented Mr. Redmond.
About BreastCheck ®
BreastCheck ® , a product of Davion Healthcare PLC, is a safe, accurate and low-cost, way to routinely monitor for breast abnormalities and is intended to be an adjunct to established procedures for the detection of breast disease, such as clinical breast examination and mammography. Abnormalities within the breast frequently produce additional breast heat. BreastCheck ® averages temperature at three areas on each breast. By comparing the temperature of corresponding areas of one breast to the other and entering the results on the BreastCheck ® Mobile App, results can be interpreted immediately.
About Breast Cancer
Breast cancer is the most common cancer in women worldwide and a leading cause of cancer-related deaths. It occurs when abnormal cells in the breast grow uncontrollably, forming tumors that may spread to other parts of the body. The American Cancer Society estimates that in the United States about 316,950 invasive and 59,080 non-invasive cases are expected in 2025 and breast cancer accounts for roughly 30% of new cancers among women. According to the World Health Organization, in 2022, an estimated 2.3 million women were newly diagnosed with breast cancer worldwide and around 670,000 die from the disease. If current trends continue, by 2050 the number of new breast cancer cases per year is projected to rise to 3.2 million globally.
About Odyssey Health, Inc.
Odyssey Health, Inc. (OTCQB: ODYY ) is a medical technology company with a focus in the area of life- saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity. Odyssey Medical Devices, Inc is a wholly owned subsidiary of Odyssey Health Inc.
For more information, visit: https://www.odysseyhealthinc.com/breastcheck
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the ability of the Company to timely and successfully close on the sub-license agreement. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to: the Company’s ability to advance the development and commercialization of the BreastCheck ® under the timelines and in accord with the milestones projected; the Company’s ability to raise capital and obtain funding, non-dilutive or otherwise, for the development and commercialization of the BreastCheck ® ; the Company’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the Company’s expectations as to the outcome of the potential benefits, effectiveness and safety of the BreastCheck ® including as to administration, manufacturing, distribution and general economic and market conditions and risks, as well as other uncertainties described in our filings with the U.S. Securities and Exchange Commission. All information set forth is as of the date hereof unless otherwise indicated. You should consider these factors in evaluating the forward-looking statements.
Media and Investors Contacts:
CG CAPITAL
Rich Cockrell
877.889.1972
investorrelations@cg.capital
FAQ**
How does Odyssey Health, Inc. (Odyssey Group International Inc ODYY) plan to differentiate BreastCheck ® in a competitive breast cancer diagnostics market projected to double in the next 8-years?
What are the specific closing conditions for the sub-licensing agreement of BreastCheck ® that Odyssey Group International Inc ODYY must meet before commercialization begins?
Can you elaborate on the expected revenue generation timeline for BreastCheck ® and how Odyssey Group International Inc ODYY aims to transition from a development-stage to a revenue-generating medtech company?
With the rising incidence of breast cancer globally, how is Odyssey Health, Inc. (Odyssey Group International Inc ODYY) positioning BreastCheck ® to address healthcare access challenges in emerging markets?
**MWN-AI FAQ is based on asking OpenAI questions about Odyssey Group International Inc (OTC: ODYY).
NASDAQ: ODYY
ODYY Trading
3.97% G/L:
$0.055 Last:
23,706 Volume:
$0.0445 Open:
